Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Connection

Philip Reigan to Neoplasms

This is a "connection" page, showing publications Philip Reigan has written about Neoplasms.

 
Connection Strength
 
 
 
1.257
 
  1. Strang JE, Astridge DD, Nguyen VT, Reigan P. Small Molecule Modulators of AMP-Activated Protein Kinase (AMPK) Activity and Their Potential in Cancer Therapy. J Med Chem. 2025 Feb 13; 68(3):2238-2254.
    View in: PubMed
    Score: 0.339
  2. Warfield BM, Reigan P. Multifunctional role of thymidine phosphorylase in cancer. Trends Cancer. 2022 06; 8(6):482-493.
    View in: PubMed
    Score: 0.277
  3. Casalvieri KA, Matheson CJ, Backos DS, Reigan P. Selective Targeting of RSK Isoforms in Cancer. Trends Cancer. 2017 04; 3(4):302-312.
    View in: PubMed
    Score: 0.197
  4. Matheson CJ, Backos DS, Reigan P. Targeting WEE1 Kinase in Cancer. Trends Pharmacol Sci. 2016 10; 37(10):872-881.
    View in: PubMed
    Score: 0.188
  5. Furtek SL, Backos DS, Matheson CJ, Reigan P. Strategies and Approaches of Targeting STAT3 for Cancer Treatment. ACS Chem Biol. 2016 Feb 19; 11(2):308-18.
    View in: PubMed
    Score: 0.181
  6. Brubaker LW, Backos DS, Nguyen VT, Reigan P, Yamamoto TM, Woodruff ER, Iwanaga R, Wempe MF, Kumar V, Persenaire C, Watson ZL, Bitler BG. Novel chromobox 2 inhibitory peptide decreases tumor progression. Expert Opin Ther Targets. 2023 Apr-May; 27(4-5):361-371.
    View in: PubMed
    Score: 0.075
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Copyright © 2025 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)